$REGN

$763.98▲ +2.2% YTD

6 SEC 13D/G filings tracked · Last updated Oct 12, 2026

Filing History

REGN ▲ +2.2% - Regeneron Pharmaceuticals, Inc.

CP $763.98▲ +2.2%Oct 12, 2026 · ThinkSabio Blog

$REGN - Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Pa…

News

REGN ▼ -0.1% - Regeneron Pharmaceuticals, Inc.

CP $726.00▲ -0.1%Oct 6, 2026 · ThinkSabio Blog

$REGN - Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026…

News

REGN ▼ -3.3% - Regeneron Pharmaceuticals, Inc.

CP $732.59▲ -3.3%Oct 1, 2026 · ThinkSabio Blog

$REGN - Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSO…

News

REGN ▼ -3.2% - Regeneron Pharmaceuticals, Inc.

CP $733.95▲ -3.2%Oct 1, 2026 · ThinkSabio Blog

$REGN - Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss…

News

REGN ▲ +1.1% - Regeneron Pharmaceuticals, Inc.

CP $759.00▲ +1.1%Oct 1, 2026 · ThinkSabio Blog

$REGN - Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies…

News

REGN ▼ -0.7% - Regeneron Pharmaceuticals, Inc.

CP $796.02▲ -0.7%Sep 24, 2026 · ThinkSabio Blog

$REGN - Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026…